The global neuromodulation devices market size is expected to reach USD 49.80 billion by 2029 from USD 30.77 billion in 2024, growing at a CAGR of 10.11% from 2024 to 2029.
As awareness regarding neuromodulation therapy is increasing among people, the number of patients opting for consultation and therapy for nerve injuries and chronic disorders has been rising.Technological advancements in the neuromodulation devices market in the form of non-invasive types of devices have fuelled market growth and have been expanding to unpenetrated regions. As the risk associated with surgery in the non-invasive type of devices is very low, a greater number of people are opting for neuromodulation surgeries. Non-invasive devices have changed the market completely as the biggest market for neuromodulation devices in the United States, which is based on the use of non-invasive devices. The prevalence of nerve injuries and chronic pain and conditions such as cancer has been rising worldwide as the population of aged citizens is increasing and the rate of obesity is rising at an alarming rate. Neuromodulation devices offer a safe and effective way to manage chronic pain. These devices work by stimulating nerves or the spinal cord, which can help to reduce pain.
Therefore, rising awareness regarding neuromodulation therapy and surgery, technological advancements in the market, and the prevalence of conditions causing disorders are the major factors driving the growth of the neuromodulation devices market.
This restricts the growth of the neuromodulation devices market in developed and underdeveloped countries like Nepal and many African countries. Due to the high cost of the treatment, many people cannot afford neuromodulation therapy. Risk is associated with neuromodulation therapy or surgery. Risk of side effects like bleeding, infection, or pain are associated with the surgery. In certain severe cases, stroke or death can also happen. This restricts the patients from considering the option of surgery for chronic disorders. In many European countries, reimbursement is given for the treatment using neuromodulation devices. But the countries where the cost of treatment is not reimbursed, the number of patients considering the neuromodulation devices treatment is very low.
Hence, the high initial as well as maintenance costs of neuromodulation devices, the risk associated with the treatment, and limited or no reimbursement of the cost of treatment are the major limitations for the growth of the neuromodulation devices market.
REPORT METRIC |
DETAILS |
Market Size Available |
2024 to 2029 |
Base Year |
2024 |
Forecast Period |
2024 to 2029 |
Segments Covered |
By Type, Application, End-User, and Region |
Various Analyses Covered |
Global, Regional and country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges; PESTLE Analysis; Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview of Investment Opportunities |
Regions Covered |
North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa |
Market Leaders Profiled |
LivaNova PLC, Abbott, Medtronic, Neuronetics, and NeuroPace Inc. are some of the notable companies in the global market. |
The non-invasive segment is predicted to account for the largest share of the global neuromodulation devices market during the forecast period. As the demand for minimally invasive procedures is increasing, the requirement for non-invasive neuromodulation devices is also increasing. The non-invasive segment includes devices such as transcranial magnetic stimulation (TMS) devices, Vagus nerve stimulators (VNS) devices, and peripheral nerve stimulators (PNS) devices. These devices are not surgically implanted and can be used at home. Thus, they are nowadays preferred by patients.
The invasive devices segment is expected to register a healthy CAGR in the global neuromodulation devices market during the forecast period. Invasive segment includes devices such as deep brain stimulators, spinal cord stimulators, and sacral nerve stimulators. These devices need to be surgically implanted in the body and require a longer recovery time as compared to non-invasive. The invasive devices are mostly used for treating Parkinson’s disease and other disorders associated with movement.
The pain management segment is estimated to account for the major share of the global neuromodulation devices market during the forecast period. As the number of patients suffering from chronic pain is increasing and neuromodulation pain management devices are an effective option for relief, the demand is rising on a Y-O-Y basis.
The neurological disorders segment is predicted to hold the second-largest share of the worldwide market during the forecast period. Neuromodulation devices are used for the treatment of neurological disorders like Parkinson’s disease, epilepsy, and depression.
The respiratory disorders segment is projected to occupy a considerable share of the global neuromodulation devices market in the coming years. Respiratory disorders such as (COPD) Chronic Obstructive Pulmonary Disease and Asthma are being treated using neuromodulation devices.
The hospitals segment is predicted to account for the largest share of the global neuromodulation devices market during the forecast period. Hospitals provide neuromodulation therapies which include spinal cord stimulation and deep brain stimulation therapy. Along with other surgeries, patients require therapy sessions which increases the demand for neuromodulation devices in hospitals.
The specialty clinics are more focused on providing treatment for neuromodulation therapy. The specialty clinics segment accounts for around 30% of the global neuromodulation devices market, as there are a smaller number of specialty clinics specialized in neuromodulation therapy. The advantage of these clinics is that the patient gets personalized treatment without any time restriction.
North America is the largest regional segment in the global neuromodulation devices market and is expected to continue its domination in the worldwide market throughout the forecast period. The growing awareness about the disorders and easy availability of treatment primarily drive the growth of the North American market. The non-invasive type of neuromodulation device is in more demand in the North American region. The U.S. is the biggest regional segment for neuromodulation devices, followed by Canada in the North American region.
Europe holds the second-largest share of the global neuromodulation devices market during the forecast period. The healthcare system in all the European countries is strengthened by the government policies that back the patients by providing treatments at affordable costs and the healthcare infrastructure is developed and well-planned. The number of patients suffering from nerve injuries is also on the rise in the European region, which is driving the European market growth.
The Asia Pacific region is predicted to witness the fastest CAGR in the global neuromodulation devices market among all the regions. The growing number of patients with cancer and chronic disorders is the prominent reason for the rise in demand for neuromodulation devices in the Asia Pacific region.
The Latin American region holds a considerable share of the global market during the forecast period. Mexico is expected to capture the largest share of the Latin American market in the coming years.
Middle East & Africa is estimated to register a steady CAGR during the forecast period.
LivaNova PLC, Abbott, Medtronic, Neuronetics and NeuroPace Inc. are some of the notable companies in the global market.
By Type
By Application
Pain Management
By End-users
Hospitals
By Region
North America
Frequently Asked Questions
Market growth is influenced by factors such as the increasing geriatric population, higher prevalence of neurological disorders, advancements in device technology, growing demand for minimally invasive procedures, and expanding applications of neuromodulation in various medical fields.
Market growth can be hindered by challenges such as regulatory hurdles, high device costs, limited awareness among patients and healthcare professionals, and the need for more clinical evidence to support certain applications.
The market's distribution varies by region. North America and Europe have historically been major markets due to advanced healthcare infrastructure, while the Asia-Pacific region is witnessing rapid growth due to improving healthcare access and increasing awareness.
Related Reports
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500
Didn’t find what you’re looking for?
TALK TO OUR ANALYST TEAM
Need something within your budget?
NO WORRIES! WE GOT YOU COVERED!
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]
Reports By Region